Risk of death and readmission among individuals with heart failure and HIV: A systematic review and meta-analysis
Yaqin Zhou(Army Medical University), Frank Qian(Boston University), Han‐Zhu Qian(Central South University), Xianhong Li(Hubei University of Medicine), Yanxiao Gao(Sun Yat-sen University), Wenru Wang(National University of Singapore), Sebhat Erqou(Cornell University), Tomas G. Neilan(Albert Einstein College of Medicine), Xuezhixing Zhang(Yale University), Honghong Wang(Central South University), Yuqing Chen(Nantong University), Markella V. Zanni(Harvard University), Raza M. Alvi(Massachusetts General Hospital), Sten H. Vermund(University of South Florida)
Cited by 6
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589